Abstract:Background Diabetic cardiovascular complication is a major cause of mortality in type 2 diabetic patients. Hyperglycemia markedly increases the risk of cardiovascular disease. Endothelial dysfunction is common in type 2 diabetes mellitus (DM) and is an early indicator of diabetic vascular disease. Therefore, it is necessary to identify the effect of different hypoglycemic agents on vascular endothelium. The aim of the study was to examine and compare the effects of metformin and gliquidone on atherosclerotic lesions in streptozotocin-induced diabetic rats. Methods Forty male Sprague-Dawley rats (age, 8 weeks; weight, 180–200 g) were included in this study and fed with a normal chow diet for 1 week. Rats (n=10) served as the normal control group (NC group) were fed with a normal chow for another 2 weeks and received an injection of saline. The rest 30 rats fed with a high-fat diet for 2 weeks and injected streptozotocin were randomly assigned to three groups (n=10 rats per group) as follow: type 2 DM group (DM group), DM + gliquidone group (GLI group) and DM + metformin group (MET group). Five weeks later, all rats were fasted overnight and taken tail blood samples for biochemical determinations. Then rats in the NC and DM groups were administrated with normal saline, while rats in the MET and GLI groups were administrated with metformin (100 mg/kg) or gliquidone (10 mg/kg), respectively. All medicines were given via intragastric administration for 8 weeks. After 16 weeks, plasma triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) were measured. The aortic arch was isolated from diabetic rats and was assessed by pathological sectioning using H&E staining. Results Metformin treatment prevented weight gain ((315.80±52.16) g vs. (318.70±68.48) g, P=0.773), improved plasma TG, HDL-C and LDL-C levels (P=0.006, 0.003, 0.001, respectively, all P <0.05). However, gliquidone showed no significant effects on plasma TG and TC levels (P=0.819, 0.053, respectively). LDL-C and HDL-C in the GLI group changed ((0.46±0.10) mmol/L vs. (0.36±0.14) mmol/L, P=0.007; (0.99±0.27) mmol/L vs. (1.11±0.18) mmol/L, P=0.049). Both metformin and gliquidone treatment lowered blood glucose levels (P=0.001, 0.004, respectively, P <0.05). Under light microscopy, no changes were observed in the aortic wall structure of each layer; the intima was smooth and the membrane elastic fibers were normal in the NC group. In the DM group, the aortic wall structure was unclear, the intima was thickened with irregular intima, and membrane elastic fibers collapsed. The aortic intima in the MET and GLI groups was smoother compared with the DM group, but the endothelial structure of the MET group was closer to that of the NC group. Conclusions Both metformin and gliquidone have anti-atherosclerotic effects. But the endothelial structure of the MET group was closer to that of the NC group. Metformin and gliquidone therapy can reduce serum level of LDL-C and increase level of HDL-C, whereas gliquidone therapy did not lose weight and decrease serum level of TG. These data may have important implications for the treatment of patients with type 2 DM.

Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance.

Gliquidone Versus Metformin: Differential Effects on Aorta in Streptozotocin Induced Diabetic Rats

Suppressive Effects of Metformin on Colorectal Adenoma Incidence and Malignant Progression

Effects of metformin on insulin sensitivity and islet beta cell secretion in obesity patients

Influence of Metformin on the serum resistin concentration in patients with impaired glucose tolerance

Effect of metformin on adipose tissue distribution and hepatic lipid content in patients with type 2 diabetes

The Beneficial Effect Of Metformin On Beta-Cell Function In Non-Obese Chinese Subjects With Newly Diagnosed Type 2 Diabetes

Metformin reduces serum CA199 levels in type 2 diabetes Chinese patients with time-effect and gender difference.

Effect of Metformin on Testosterone Levels in Male Patients With Type 2 Diabetes Mellitus Treated With Insulin

Effects of Metformin and Pioglitazone on Plasma Ghrelin in Patients with Newly Diagnosed Abnormal Glucose Metabolism and Abdominal Obesity

Effect of oral metformin on gut microbiota characteristics and metabolite fractions in normal-weight type 2 diabetic mellitus patients

The effect of metformin combined with liraglutide on gut microbiota of Chinese patients with type 2 diabetes

Effect of Metformin on Fibroblast Growth Factor-21 Levels in Patients with Newly Diagnosed Type 2 Diabetes.

Clinical efficacy of metformin in familial adenomatous polyposis and the effect of intestinal flora

Different Interactive Effects of Metformin and Acarbose with Dietary Macronutrient Intakes on Patients with Type 2 Diabetes Mellitus: Novel Findings from the MARCH Randomized Trial in China

Effect of Metformin on Breast Density in Overweight/Obese Premenopausal Women

Effect of Metformin Treatment on Cardiovascular Events and Restenosis after Coronary Stenting in Patients with Impaired Glucose Tolerance Accompanied by Coronary Heart Disease

Efficacy of Metformin in Preventing Progression to Diabetes in a Chinese Population with Impaired Glucose Regulation: Protocol for a Multicentre, Open‐label, Randomized Controlled Clinical Study

Effects of acarbose and metformin on thyroid function and thyroid hormone sensitivity in type 2 diabetes patients: a post-hoc analysis of the MARCH study

Effect of metformin on Wnt5a in individuals new-onset type 2 diabetes with different body mass indexes: The evidences from the real word research

Effect of metformin on gut microbiota imbalance in patients with T2DM, and the value of probiotic supplementation